Zydus Cadila seeks DCGI nod for use of hepatitis drug for COVID-19 treatment

Drug firm Zydus Cadila on Monday said it has sought approval from the domestic drug regulator Drugs Controller General of India (DCGI) for the additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating COVID-19. Phase-III clinical trials with Pegylated Interferon Alpha 2b, which the company sells under the brand name ‘PegiHep’ has shown promising results in treating COVID-19, Zydus Cadila said in a statement.